Cancer Genetics Inc (NASDAQ:CGIX) shares gapped down prior to trading on Thursday . The stock had previously closed at $0.47, but opened at $0.35. Cancer Genetics shares last traded at $0.30, with a volume of 9862773 shares trading hands.
A number of research firms have issued reports on CGIX. ValuEngine upgraded shares of Cancer Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Maxim Group restated a “hold” rating on shares of Cancer Genetics in a report on Tuesday, November 20th. Finally, HC Wainwright set a $3.00 target price on shares of Cancer Genetics and gave the company a “buy” rating in a report on Wednesday, September 19th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $4.50.
The firm has a market cap of $9.71 million, a PE ratio of -0.34 and a beta of 0.96. The company has a current ratio of 0.46, a quick ratio of 0.46 and a debt-to-equity ratio of 0.05.
A number of large investors have recently added to or reduced their stakes in CGIX. Renaissance Technologies LLC lifted its holdings in shares of Cancer Genetics by 15.0% during the 3rd quarter. Renaissance Technologies LLC now owns 675,200 shares of the medical research company’s stock worth $702,000 after acquiring an additional 87,900 shares during the period. Perkins Capital Management Inc. lifted its holdings in shares of Cancer Genetics by 28.1% during the 3rd quarter. Perkins Capital Management Inc. now owns 1,287,250 shares of the medical research company’s stock worth $1,339,000 after acquiring an additional 282,700 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Cancer Genetics by 119.8% during the 3rd quarter. Vanguard Group Inc. now owns 532,426 shares of the medical research company’s stock worth $554,000 after acquiring an additional 290,146 shares during the period. Finally, Vanguard Group Inc lifted its holdings in shares of Cancer Genetics by 119.8% during the 3rd quarter. Vanguard Group Inc now owns 532,426 shares of the medical research company’s stock worth $554,000 after acquiring an additional 290,146 shares during the period. Institutional investors own 14.76% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Cancer Genetics (CGIX) Shares Gap Down to $0.35” was originally published by WKRB News and is owned by of WKRB News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.wkrb13.com/2019/01/12/cancer-genetics-cgix-shares-gap-down-to-0-35.html.
Cancer Genetics Company Profile (NASDAQ:CGIX)
Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Featured Story: What is a stock buyback?
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.